Top

Neurological Sciences

Published in:

01-07-2020 | Stroke | Original Article

The influence of statins on the risk of post-stroke epilepsy

Authors: Bruno Kusznir Vitturi, Rubens José Gagliardi

Published in: Neurological Sciences | Issue 7/2020

Abstract

Background

Currently, statins are widely used for secondary prevention of stroke due to their pleiotropic neuroprotective effects. Epilepsy is a common complication of cerebrovascular diseases. The purpose of this study was to evaluate the effect of statin therapy on the occurrence of post-stroke epilepsy (PSE).

Methods

In this prospective cohort study, patients who suffered an ischemic stroke and without history of epilepsy before stroke were enrolled. At baseline, patients were classified according to the particularities of statin therapy. Statin use onset and adherence to treatment were registered as well. After a follow-up period of 1 year, we assessed the occurrence of seizures and PSE.

Results

Among the 477 patients included in our cohort, there were 91 (19.1%) patients without statins, 160 (33.5%) with simvastatin 20 mg, 180 (37.7%) with simvastatin 40 mg, and 46 (9.6%) with high-potency statins. Overall, PSE emerged in 53 (11.1%) patients. PSE was significantly more prevalent among those who did not receive statins and those with lower doses of simvastatin. Acute onset of statin use was associated with reduced odds of having PSE.

Conclusion

Adequate treatment with statins after stroke may lower the risk of PSE.

Lossius MI, Rønning OM, Slapø GD, Mowinckel P, Gjerstad L (2005) Poststroke epilepsy: occurrence and predictors - a long-term prospective controlled study (Akershus Stroke Study). Epilepsia. 46(8):1246–1251. https://doi.org/10.1111/j.1528-1167.2005.57904.xCrossRef

Jungehulsing GJ, Heuschmann PU, Holtkamp M, Schwab S, Kolominsky-Rabas PL (2013) Incidence and predictors of post-stroke epilepsy. Acta Neurol Scand 127(6):427–430. https://doi.org/10.1111/ane.12070CrossRef

Arntz RM, Maaijwee NAM, Rutten-Jacobs LCA et al (2013) Epilepsy after TIA or stroke in young patients impairs long-term functional outcome the future study. Neurology. 81(22):1907–1913. https://doi.org/10.1212/01.wnl.0000436619.25532.f3CrossRef

Arntz RM, Rutten-Jacobs LCA, Maaijwee NAM et al (2015) Poststroke epilepsy is associated with a high mortality after a stroke at young age: follow-up of transient ischemic attack and stroke patients and unelucidated risk factor evaluation study. Stroke. 46(8):2309–2311. https://doi.org/10.1161/STROKEAHA.115.010115CrossRef

Winter Y, Daneshkhah N, Galland N, Kotulla I, Krüger A, Groppa S (2018) Health-related quality of life in patients with poststroke epilepsy. Epilepsy Behav 80:303–306. https://doi.org/10.1016/j.yebeh.2017.12.037CrossRef

Castilla-Guerra L, MDC F-M, Leon-Jimenez D, Rico-Corral MA (2019) Statins in ischemic stroke prevention: what have we learned in the post-SPARCL (The Stroke Prevention by Aggressive Reduction in Cholesterol Levels) decade? Curr Treat Options Neurol 21(5):22. https://doi.org/10.1007/s11940-019-0563-4CrossRef

Squizzato A, Romualdi E, Dentali F, Ageno W (2012) Statins for acute ischemic stroke. Stroke. 43:e18–e19. https://doi.org/10.1161/STROKEAHA.111.638940CrossRef

Adams HP, Bendixen BH, Kappelle LJ et al (2011) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 24(1):35–41. https://doi.org/10.1161/01.str.24.1.35CrossRef

Beghi E, D’Alessandro R, Beretta S et al (2011) Incidence and predictors of acute symptomatic seizures after stroke. Neurology. 77:1785–1793CrossRef

10.

Kusznir Vitturi B, José GR (2019) Use of CHADS2 and CHA2DS2-VASc scores to predict prognosis after stroke. Rev Neurol (Paris) (19):30469–30462. https://doi.org/10.1016/j.neurol.2019.05.001

11.

Stefanidou M, Das RR, Beiser AS, Sundar B, Kelly-Hayes M, Kase CS, Devinsky O, Seshadri S, Friedman D (2017) Incidence of seizures following initial ischemic stroke in a community-based cohort: the Framingham Heart Study. Seizure. 47:105–110. https://doi.org/10.1016/j.seizure.2017.03.009CrossRef

12.

Bentes C, Martins H, Peralta AR et al (2017) Post-stroke seizures are clinically underestimated. J Neurol 264(9):1978–1985. https://doi.org/10.1007/s00415-017-8586-9CrossRef

13.

Holtkamp M, Beghi E, Benninger F, Kälviäinen R, Rocamora R, Christensen H (2017) European Stroke Organisation guidelines for the management of post-stroke seizures and epilepsy. Eur Stroke J 2(2):103–115. https://doi.org/10.1177/2396987317705536CrossRefPubMedCentral

14.

Ferro JM, Pinto F (2004) Poststroke epilepsy: epidemiology, pathophysiology and management. Drugs Aging 21(10):639–653. https://doi.org/10.2165/00002512-200421100-00003CrossRef

15.

Camilo O, Goldstein LB (2004) Seizures and epilepsy after ischemic stroke. Stroke. 35(7):1769–1775. https://doi.org/10.1161/01.STR.0000130989.17100.96CrossRef

16.

Silverman IE, Restrepo L, Mathews GC (2002) Poststroke seizures. Arch Neurol 59(2):195–201. https://doi.org/10.1001/archneur.59.2.195CrossRef

17.

Myint PK, Staufenberg EFA, Sabanathan K (2006) Post-stroke seizure and post-stroke epilepsy. Postgrad Med J 82(971):568–572. https://doi.org/10.1136/pgmj.2005.041426CrossRefPubMedCentral

18.

Sarecka-Hujar B, Kopyta I (2019) Poststroke epilepsy: current perspectives on diagnosis and treatment. Neuropsychiatr Dis Treat 15:95–103. https://doi.org/10.2147/NDT.S169579CrossRef

19.

Pitkänen A, Roivainen R, Lukasiuk K (2016) Development of epilepsy after ischaemic stroke. Lancet Neurol 15(2):185–197. https://doi.org/10.1016/S1474-4422(15)00248-3CrossRef

20.

Rumbach L, Sablot D, Berger E, Tatu L, Vuillier F, Moulin T (2012) Status epilepticus in stroke: report on a hospital-based stroke cohort. Neurology. 54(2):350–354. https://doi.org/10.1212/wnl.54.2.350CrossRef

21.

Lin HW, Ho YF, Lin FJ (2018) Statin use associated with lower risk of epilepsy after intracranial haemorrhage: a population-based cohort study. Br J Clin Pharmacol 84(9):1970–1979. https://doi.org/10.1111/bcp.13626CrossRefPubMedCentral

22.

Guo J, Guo J, Li J, Zhou M, Qin F, Zhang S, Wu B, He L, Zhou D (2015) Statin treatment reduces the risk of poststroke seizures. Neurology. 85(8):701–707. https://doi.org/10.1212/wnl.0000000000001814CrossRef

23.

Pande SD, Lwin MT, Kyaw KM, Khine AA, Thant AA, Win MM, Morris J (2018) Post-stroke seizure—do the locations, types and managements of stroke matter? Epilepsia Open 3(3):392–398. https://doi.org/10.1002/epi4.12249CrossRefPubMedCentral

24.

Tramacere I, Boncoraglio GB, Banzi R, del Giovane C, Kwag KH, Squizzato A, Moja L (2019) Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis. BMC Med 17(1):67. https://doi.org/10.1186/s12916-019-1298-5doi:10.1186/s12916-019-1298-5CrossRefPubMedCentral

25.

Prinz V, Endres M (2011) Statins and stroke: prevention and beyond. Curr Opin Neurol 24(1):75–80. https://doi.org/10.1097/WCO.0b013e3283424c53CrossRef

26.

de Oliveira CV, Grigoletto J, Canzian JM et al (2018) Effect of atorvastatin on behavioral alterations and neuroinflammation during epileptogenesis. Epilepsy Behav 78:109–117. https://doi.org/10.1016/j.yebeh.2017.10.021CrossRef

27.

Sehar N, Agarwal NB, Vohora D, Raisuddin S (2015) Atorvastatin prevents development of kindling by modulating hippocampal levels of dopamine, glutamate, and GABA in mice. Epilepsy Behav 42:48–53. https://doi.org/10.1016/j.yebeh.2014.11.011CrossRef

28.

Xie C, Sun J, Qiao W, Lu D, Wei L, Na M, Song Y, Hou X, Lin Z (2011) Administration of simvastatin after kainic acid-induced status epilepticus restrains chronic temporal lobe epilepsy. PLoS One 6(9):e24966. https://doi.org/10.1371/journal.pone.0024966CrossRefPubMedCentral

29.

Sierra S, Ramos MC, Molina P, Esteo C, Vázquez JA, Burgos JS (2011) Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis 23(2):307–318. https://doi.org/10.3233/JAD-2010-101179CrossRef

30.

De Simoni MG, Perego C, Ravizza T et al (2000) Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. Eur J Neurosci 12(7):2623–2633. https://doi.org/10.1046/j.1460-9568.2000.00140.xCrossRef

31.

Vivanco-Hidalgo RM, Elosua R, Gómez González A et al (2017) People with epilepsy receive more statins than the general population but have no higher cardiovascular risk: results from a cross-sectional study. Eur J Neurol 24(2):419–426. https://doi.org/10.1111/ene.13222CrossRef

32.

Ní Chróinín D, Asplund K, Åsberg S, Callaly E, Cuadrado-Godia E, Díez-Tejedor E, di Napoli M, Engelter ST, Furie KL, Giannopoulos S, Gotto AM Jr, Hannon N, Jonsson F, Kapral MK, Martí-Fàbregas J, Martínez-Sánchez P, Milionis HJ, Montaner J, Muscari A, Pikija S, Probstfield J, Rost NS, Thrift AG, Vemmos K, Kelly PJ (2013) Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational studies and randomized trials. Stroke. 44(2):448–456. https://doi.org/10.1161/STROKEAHA.112.668277CrossRef

33.

Chróinín DN, Callaly EL, Duggan J et al (2011) Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke: the North Dublin population stroke study. Stroke 42(4):1021–1029. https://doi.org/10.1161/STROKEAHA.110.596734CrossRef

34.

Kusznir Vitturi B, Barreto Cabral F, Mella CC (2019) Outcomes of pregnant women with refractory epilepsy. Seizure. 69:251–257. https://doi.org/10.1016/j.seizure.2019.05.009CrossRef

35.

Colivicchi F, Bassi A, Santini M, Caltagirone C (2007) Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke. 38(10):2652–2657. https://doi.org/10.1161/STROKEAHA.107.487017CrossRef

36.

Kusznir Vitturi B, José GR (2019) The role of statins in cardioembolic stroke. J Clin Neurosci (19):31774–31776. https://doi.org/10.1016/j.jocn.2019.12.028

Title: The influence of statins on the risk of post-stroke epilepsy
Authors: Bruno Kusznir Vitturi
Rubens José Gagliardi
Publication date: 01-07-2020
Publisher: Springer International Publishing
Keywords: Stroke
Statins
Simvastatin
Epilepsy
Published in: Neurological Sciences / Issue 7/2020
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04298-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The influence of statins on the risk of post-stroke epilepsy

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2020

Contrast sensitivity impairment in drug-naïve Parkinson’s disease patients associates with early cognitive decline

Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy

Autosomal dominant SPG9: intrafamilial variability and onset during pregnancy

The effectiveness of various cytotherapeutic strategies for the treatment of ischemic stroke: a Bayesian network meta-analysis of randomized controlled trials

Impact of brain atrophy on tDCS and HD-tDCS current flow: a modeling study in three variants of primary progressive aphasia

Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study